Strategically acquiring and approving cancer drugs

A lean, entrepreneurial approach is enabling specialty pharma company EUSA Pharma to outcompete larger rivals.

Like Comment
Page of
Go to the profile of EUSA Pharma

EUSA Pharma

Founded in March 2015, EUSA Pharma is a profitable commercial-stage specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. EUSA Pharma has a portfolio of approved Oncology therapeutic and supportive care products including: FOTIVDA® (tivozanib) for the treatment of advanced RCC, QARZIBA® (dinutuximab beta) for the treatment of HR Neuroblastoma, Caphosol® and Caphosol® DISPERSIBLE, for the treatment and prevention of Oral Mucositis.

No comments yet.